JPH10509955A - 二次性免疫不全症の治療法 - Google Patents
二次性免疫不全症の治療法Info
- Publication number
- JPH10509955A JPH10509955A JP8517007A JP51700796A JPH10509955A JP H10509955 A JPH10509955 A JP H10509955A JP 8517007 A JP8517007 A JP 8517007A JP 51700796 A JP51700796 A JP 51700796A JP H10509955 A JPH10509955 A JP H10509955A
- Authority
- JP
- Japan
- Prior art keywords
- thymosin
- ncm
- natural
- treatment
- ril
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57581—Thymosin; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Endocrinology (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Processing Of Meat And Fish (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.患者における細胞性免疫不全症を治療する方法であって、 細胞性免疫不全症の存在を決定する工程、および 胸腺ペプチドの有効量を、天然サイトカイン製剤の有効量と共に、患者に共投 与する工程、を含む上記治療方法。 2.該胸腺ペプチドが、チモシンα1、チモシンα1類似体、チモシンα1フラグ メント、チモシンα11、プロチモシン並びにチモシンα1配列を含む胸腺ペプチ ド、類似体およびフラグメントからなる群から選択される、請求の範囲第1項に 記載の方法。 3.該胸腺ペプチドがチモシンα1である、請求の範囲第2項に記載の方法。 4.天然サイトカイン製剤が、天然サイトカイン混合物(NCM)、天然インタ ーロイキン混合物(NIM)および天然インターロイキン製剤(NI)からなる 群から選択される、請求の範囲第1項に記載の方法。 5.IL−1を10-2000pg/ml、IL−2を100-500単位/ml、IL−6を250-10,0 00pg/ml、IL−8を12,000-100,000pg/ml、IL−12を100-10,000pg/ml、I FN−γを50-15,000pg/ml、TNF−αを50-15,000pg/ml、CSF−Gを50-150 0pg/ml、CSF−GMを10-1560pg/ml、および微量のIL−3、IL−4、IL −7を含むサイトカインプロフィールを含む請求の範囲第4項に記載のサイトカ インの天然混合物。 6.治療される細胞性免疫不全症が、加齢、癌、HIV感染および他の急性およ び慢性感染により生じる細胞性免疫不全症群から選択される、請求の範囲第1項 に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/341,424 | 1994-11-17 | ||
US08/341,424 US5632983A (en) | 1994-11-17 | 1994-11-17 | Method for treating secondary immunodeficiency |
PCT/US1995/015038 WO1996015800A1 (en) | 1994-11-17 | 1995-11-16 | Method for treating secondary immunodeficiency |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006224746A Division JP2006306898A (ja) | 1994-11-17 | 2006-08-21 | 二次性免疫不全症の治療法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH10509955A true JPH10509955A (ja) | 1998-09-29 |
JP4416839B2 JP4416839B2 (ja) | 2010-02-17 |
Family
ID=23337510
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51700796A Expired - Fee Related JP4416839B2 (ja) | 1994-11-17 | 1995-11-16 | 二次性免疫不全症の治療法 |
JP2006224746A Withdrawn JP2006306898A (ja) | 1994-11-17 | 2006-08-21 | 二次性免疫不全症の治療法 |
JP2008246964A Pending JP2009029830A (ja) | 1994-11-17 | 2008-09-25 | 二次性免疫不全症の治療法 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006224746A Withdrawn JP2006306898A (ja) | 1994-11-17 | 2006-08-21 | 二次性免疫不全症の治療法 |
JP2008246964A Pending JP2009029830A (ja) | 1994-11-17 | 2008-09-25 | 二次性免疫不全症の治療法 |
Country Status (12)
Country | Link |
---|---|
US (1) | US5632983A (ja) |
EP (2) | EP2036569A3 (ja) |
JP (3) | JP4416839B2 (ja) |
AT (1) | ATE419860T1 (ja) |
AU (1) | AU702770B2 (ja) |
CA (1) | CA2205405C (ja) |
DE (1) | DE69535904D1 (ja) |
DK (1) | DK0787008T3 (ja) |
ES (1) | ES2320280T3 (ja) |
MX (1) | MX9703627A (ja) |
PT (1) | PT787008E (ja) |
WO (1) | WO1996015800A1 (ja) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005510491A (ja) * | 2001-10-26 | 2005-04-21 | イミュノ−アールエックス, インコーポレイテッド | 免疫抑制を逆転させるための免疫治療 |
JP2009530308A (ja) * | 2006-03-14 | 2009-08-27 | アイ アール エックス セーラピューティクス, インコーポレイテッド | 免疫が抑制された患者のための免疫療法 |
US8017129B2 (en) | 2006-06-15 | 2011-09-13 | SciClone Pharmaceuticals International Ltd | Use of thymosin alpha 1 for preparing a medicament for the treatment of stage IV malignant melanoma |
JP2012087150A (ja) * | 2000-10-27 | 2012-05-10 | Irx Therapeutics Inc | 免疫抑制された患者のためのワクチン免疫療法 |
JP2012144579A (ja) * | 2003-08-08 | 2012-08-02 | Irx Therapeutics Inc | 免疫抑制された患者のためのワクチン免疫治療 |
US9333238B2 (en) | 2009-12-08 | 2016-05-10 | Irx Therapeutics, Inc. | Method of immunotherapy for treament of human papillomavirus infection |
US9492517B2 (en) | 2000-10-27 | 2016-11-15 | Irx Therapeutics, Inc. | Vaccine immunotherapy |
US9539320B2 (en) | 2009-05-15 | 2017-01-10 | Irx Therapeutics, Inc. | Vaccine immunotherapy |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5674483A (en) * | 1995-01-31 | 1997-10-07 | National Jewish Medical And Research Center | Treatment for diseases involving inflammation |
DE19608280A1 (de) * | 1996-02-23 | 1997-08-28 | Strathmann Ag & Co | Arzneimittel zur kausalen Therapie von HIV- oder SIV-Infektionen |
US6261537B1 (en) | 1996-10-28 | 2001-07-17 | Nycomed Imaging As | Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors |
CA2307345A1 (en) | 1997-10-17 | 1999-04-29 | University Of South Florida | Method to diagnose and monitor cellular immune deficiencies |
US6197751B1 (en) * | 1997-11-10 | 2001-03-06 | The United States Of America As Represented By The Department Of Health And Human Services | Thymosin α1 promotes tissue repair, angiogenesis and cell migration |
IT1298487B1 (it) * | 1997-12-19 | 2000-01-10 | Sigma Tau Ind Farmaceuti | Composizioni farmaceutiche comprendenti pentraxina lunga ptx3 per la terapia di patologie di tipo infettivo, infiammatorio o tumorale, |
US6440448B1 (en) * | 1998-03-16 | 2002-08-27 | Joseph Intelisano | Food supplement/herbal composition for health enhancement |
US6348050B1 (en) * | 1999-04-30 | 2002-02-19 | Medtronic, Inc. | Infusion systems for creating microenvironments in a living body |
US7030219B2 (en) | 2000-04-28 | 2006-04-18 | Johns Hopkins University | B7-DC, Dendritic cell co-stimulatory molecules |
US20050201981A1 (en) * | 2004-03-10 | 2005-09-15 | Chih-Ping Liu | Method of optimizing treatment with interferon-tau |
US20050118137A1 (en) * | 2000-07-19 | 2005-06-02 | Chih-Ping Liu | Method of treatment using interferon-tau |
US20040247565A1 (en) * | 2000-07-19 | 2004-12-09 | Chih-Ping Liu | Method of treatment using interferon-tau |
US20050084478A1 (en) * | 2000-10-17 | 2005-04-21 | Chih-Ping Liu | Combination therapy using interferon-tau |
US7431920B2 (en) * | 2000-07-19 | 2008-10-07 | Pepgen Corporation | Method of treating IL-10 deficiency |
US20050118138A1 (en) * | 2000-07-19 | 2005-06-02 | Chih-Ping Liu | Method of treatment using interferon-tau |
US20050226845A1 (en) * | 2004-03-10 | 2005-10-13 | Chih-Ping Liu | Method of treatment using interferon-tau |
WO2002022159A1 (en) | 2000-09-11 | 2002-03-21 | Therapro Technologies, Inc. | Thionin as an antineoplastic and immunostimulant |
US20070031372A1 (en) * | 2004-08-05 | 2007-02-08 | Hadden John W | Vaccine immunotherapy for immune suppressed patients |
US20070154399A1 (en) * | 2000-10-27 | 2007-07-05 | Hadden John W | Immunotherapy for immune suppressed patients |
JP4029041B2 (ja) | 2001-01-10 | 2008-01-09 | アメリカ合衆国 | sFRPおよびsFRPと相互作用するペプチドモチーフならびにそれらの使用法 |
UA80957C2 (en) * | 2001-11-01 | 2007-11-26 | Sciclone Pharmaceuticals Inc | Method of administering a thymosin alpha 1 peptide |
UA78726C2 (en) * | 2001-11-01 | 2007-04-25 | Sciclone Pharmaceuticals Inc | Pharmaceutical composition of thymosin alpha 1 conjugated with polyethylene glycol, method for production, and method for treatment |
CA2520400C (en) | 2003-03-28 | 2013-02-19 | Sciclone Pharmaceuticals, Inc. | Treatment of aspergillus infections with thymosin alpha 1 |
US20100311656A1 (en) * | 2003-04-23 | 2010-12-09 | Sciclone Pharmaceuticals, Inc. | Treatment or prevention of respiratory viral infections with alpha thymosin peptides |
US6896879B2 (en) * | 2003-07-03 | 2005-05-24 | Cel-Sci Corporation | Method of pre-sensitizing cancer prior to treatment with radiation and/or chemotherapy and a novel cytokine mixture |
US20060078942A1 (en) * | 2004-03-10 | 2006-04-13 | Pepgen Corporation | Method of treatment using interferon-tau |
US20080025948A1 (en) * | 2004-03-10 | 2008-01-31 | Chih-Ping Liu | Methods of Treatment Using Interferon-Tau |
WO2006015137A2 (en) * | 2004-07-30 | 2006-02-09 | Cel-Sci Corporation | A method for managing cholesterol with a serum-free and mitogen free cytokine mixture |
ES2389452T3 (es) * | 2006-05-02 | 2012-10-26 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Uso de timosina 1, sola o en combinación con PTX3 o ganciclovir, para el tratamiento de infección por citomegalovirus |
CA2706445C (en) | 2007-11-28 | 2019-07-23 | Irx Therapeutics, Inc. | Production of apoptosis-resistant t-lymphocytes for use in cancer therapy |
CA2734908A1 (en) * | 2008-08-25 | 2010-03-11 | Amplimmune, Inc. | Compositions of pd-1 antagonists and methods of use |
AU2009288289B2 (en) * | 2008-08-25 | 2012-11-08 | Amplimmune, Inc. | PD-1 antagonists and methods of use thereof |
US8066949B2 (en) * | 2008-09-26 | 2011-11-29 | Exxonmobil Research & Engineering Company | Scrubber for fluid coker unit |
JP2012526149A (ja) * | 2009-05-08 | 2012-10-25 | サイクローン・ファーマシューティカルズ・インコーポレイテッド | ワクチン増強剤としてのαチモシンペプチド |
US20110070269A1 (en) * | 2009-09-24 | 2011-03-24 | Therapro Technologies, Inc. | Lipopolysaccharide isolated from pyrularia tissue and/or pyrularia-associated bacteria and uses thereof |
CN110101843A (zh) * | 2018-02-01 | 2019-08-09 | 北京科诺科服生物科技有限公司 | 一种抗肿瘤蛋白质及其应用 |
WO2023072850A1 (en) * | 2021-10-25 | 2023-05-04 | Ellennbe Gmbh | Pharmaceutical composition comprising an immunomodulatory substance for treating diseases |
WO2024084038A1 (en) * | 2022-10-20 | 2024-04-25 | Ellennbe Gmbh | Platform technology for treatment of inflammatory, immunological and/or autoimmunological diseases |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4079127A (en) | 1976-10-28 | 1978-03-14 | Board Of Regents Of The University Of Texas | Thymosin alpha 1 |
US4116951A (en) * | 1977-04-22 | 1978-09-26 | Hoffmann-La Roche Inc. | [Asn2 ]-thymosin α1 and analogs thereof |
US4148788A (en) | 1978-01-23 | 1979-04-10 | Hoffmann-La Roche Inc. | Synthesis of thymosin α1 |
DE2919592A1 (de) * | 1979-05-15 | 1981-01-15 | Max Planck Gesellschaft | Verfahren zur herstellung von thymosin- alpha 1 und derivaten davon |
DE3100974A1 (de) * | 1980-01-18 | 1982-01-21 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen | Thymosin(alpha)(pfeil abwaerts)1(pfeil abwaerts)-fragmente enthaltende arzneimittel mit immunregulierender wirkung, und thymosin(alpha)(pfeil abwaerts)1(pfeil abwaerts)-fragmente |
US4470926A (en) * | 1980-01-18 | 1984-09-11 | Max-Planck-Gesellschaft zur F/o/ rderung der Wissenschaften e.V. | Medicaments containing thymosin alpha 1 fragments and having an immunostimulant action, and fragments of thymosin alpha 1 |
US4612365A (en) * | 1980-03-25 | 1986-09-16 | Max-Planck-Gesellschaft Zur Foederung Der Wissenschaften | Medicaments containing alpha 1-thymosin and having an immuno regulatory action and alpha 1-thymosin fragments |
US4293455A (en) | 1980-04-07 | 1981-10-06 | Rockefeller University | N.sup.α -Desacetylthymosinα1 and process |
US4390623A (en) | 1980-10-02 | 1983-06-28 | Hooper Trading Company | Serum-free and mitogen-free T-cell growth factor and process for making same |
US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
US4448879A (en) | 1981-03-26 | 1984-05-15 | Hooper Trading Company | High yield process for in vitro production of serum-free and mitogen-free interleukin-2 |
US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
US4504415A (en) | 1983-04-04 | 1985-03-12 | Hoffman-La Roche Inc. | Synthesis of thymosin α1 and desacetyl thymosin α1 |
US4518584A (en) | 1983-04-15 | 1985-05-21 | Cetus Corporation | Human recombinant interleukin-2 muteins |
FR2546267B1 (fr) | 1983-05-19 | 1985-07-26 | Aubry Cie Sa | Structure d'enveloppe ou de panneau composite multicouches |
US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
US4614731A (en) | 1983-09-15 | 1986-09-30 | Hoffmann-La Roche Inc. | Peptide having immunopotentiating activity similar to thymosin alpha1 |
US4659694A (en) * | 1983-10-27 | 1987-04-21 | Hoffmann-La Roche Inc. | Prothymosin alpha |
US4569790A (en) | 1984-03-28 | 1986-02-11 | Cetus Corporation | Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions |
US4716148A (en) * | 1984-08-13 | 1987-12-29 | Hoffman-La Roche Inc. | Prothymosin alpha |
US5093114A (en) * | 1985-03-16 | 1992-03-03 | Burroughs Wellcome Co. | Treatment of human viral infections |
US4935233A (en) * | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
IT1238231B (it) * | 1989-12-18 | 1993-07-12 | Consiglio Nazionale Ricerche | Impiego di immunomodulanti come agenti sinergici di chemioterapici nella terapia dei tumori |
CN1094310A (zh) * | 1992-12-15 | 1994-11-02 | 托马斯·C·梅里根 | 人体免疫缺陷性病毒感染用组合式化学疗法 |
-
1994
- 1994-11-17 US US08/341,424 patent/US5632983A/en not_active Expired - Lifetime
-
1995
- 1995-11-16 AU AU42400/96A patent/AU702770B2/en not_active Ceased
- 1995-11-16 AT AT95940751T patent/ATE419860T1/de active
- 1995-11-16 WO PCT/US1995/015038 patent/WO1996015800A1/en active Application Filing
- 1995-11-16 ES ES95940751T patent/ES2320280T3/es not_active Expired - Lifetime
- 1995-11-16 DK DK95940751T patent/DK0787008T3/da active
- 1995-11-16 JP JP51700796A patent/JP4416839B2/ja not_active Expired - Fee Related
- 1995-11-16 PT PT95940751T patent/PT787008E/pt unknown
- 1995-11-16 EP EP09150028A patent/EP2036569A3/en not_active Withdrawn
- 1995-11-16 DE DE69535904T patent/DE69535904D1/de not_active Expired - Lifetime
- 1995-11-16 EP EP95940751A patent/EP0787008B1/en not_active Expired - Lifetime
- 1995-11-16 CA CA002205405A patent/CA2205405C/en not_active Expired - Fee Related
-
1997
- 1997-05-16 MX MX9703627A patent/MX9703627A/es not_active IP Right Cessation
-
2006
- 2006-08-21 JP JP2006224746A patent/JP2006306898A/ja not_active Withdrawn
-
2008
- 2008-09-25 JP JP2008246964A patent/JP2009029830A/ja active Pending
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012087150A (ja) * | 2000-10-27 | 2012-05-10 | Irx Therapeutics Inc | 免疫抑制された患者のためのワクチン免疫療法 |
JP2013075922A (ja) * | 2000-10-27 | 2013-04-25 | Irx Therapeutics Inc | 免疫抑制された患者のためのワクチン免疫療法 |
US8784796B2 (en) | 2000-10-27 | 2014-07-22 | Irx Therapeutics, Inc. | Vaccine immunotherapy for treating hepatocellular cancer in immune suppressed patients |
US9789172B2 (en) | 2000-10-27 | 2017-10-17 | Irx Therapeutics, Inc. | Vaccine immunotherapy for treating lymphoma in immune suppressed patients |
US9492517B2 (en) | 2000-10-27 | 2016-11-15 | Irx Therapeutics, Inc. | Vaccine immunotherapy |
US9492519B2 (en) | 2000-10-27 | 2016-11-15 | Irx Therapeutics, Inc. | Vaccine immunotherapy |
US9789173B2 (en) | 2000-10-27 | 2017-10-17 | Irx Therapeutics, Inc. | Vaccine immunotherapy for treating cervical cancer in immune suppressed patients |
JP2005510491A (ja) * | 2001-10-26 | 2005-04-21 | イミュノ−アールエックス, インコーポレイテッド | 免疫抑制を逆転させるための免疫治療 |
JP2012144579A (ja) * | 2003-08-08 | 2012-08-02 | Irx Therapeutics Inc | 免疫抑制された患者のためのワクチン免疫治療 |
JP2009530308A (ja) * | 2006-03-14 | 2009-08-27 | アイ アール エックス セーラピューティクス, インコーポレイテッド | 免疫が抑制された患者のための免疫療法 |
US8017129B2 (en) | 2006-06-15 | 2011-09-13 | SciClone Pharmaceuticals International Ltd | Use of thymosin alpha 1 for preparing a medicament for the treatment of stage IV malignant melanoma |
US8029799B2 (en) | 2006-06-15 | 2011-10-04 | Sciclone Pharmaceuticals, Inc. | Use of thymosin alpha 1 for preparing a medicament for the treatment of stage IV malignant melanoma |
US9566331B2 (en) | 2009-05-15 | 2017-02-14 | Irx Therapeutics, Inc. | Vaccine immunotherapy |
US9539320B2 (en) | 2009-05-15 | 2017-01-10 | Irx Therapeutics, Inc. | Vaccine immunotherapy |
US9333238B2 (en) | 2009-12-08 | 2016-05-10 | Irx Therapeutics, Inc. | Method of immunotherapy for treament of human papillomavirus infection |
US9931378B2 (en) | 2009-12-08 | 2018-04-03 | Irx Therapeutics, Inc. | Method of immunotherapy for treatment of human papillomavirus infection |
Also Published As
Publication number | Publication date |
---|---|
JP4416839B2 (ja) | 2010-02-17 |
EP0787008A4 (en) | 1999-02-10 |
AU4240096A (en) | 1996-06-17 |
AU702770B2 (en) | 1999-03-04 |
EP0787008A1 (en) | 1997-08-06 |
ATE419860T1 (de) | 2009-01-15 |
CA2205405C (en) | 2003-02-04 |
EP2036569A2 (en) | 2009-03-18 |
EP0787008B1 (en) | 2009-01-07 |
MX9703627A (es) | 1998-07-31 |
JP2006306898A (ja) | 2006-11-09 |
DK0787008T3 (da) | 2009-05-11 |
EP2036569A3 (en) | 2009-04-01 |
WO1996015800A1 (en) | 1996-05-30 |
JP2009029830A (ja) | 2009-02-12 |
DE69535904D1 (de) | 2009-02-26 |
ES2320280T3 (es) | 2009-05-20 |
PT787008E (pt) | 2009-03-23 |
CA2205405A1 (en) | 1996-05-30 |
US5632983A (en) | 1997-05-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH10509955A (ja) | 二次性免疫不全症の治療法 | |
JP4440342B2 (ja) | 二次性免疫不全症の治療用薬剤の製造方法 | |
JP3825467B2 (ja) | インターロイキン―7を用いた選定免疫療法 | |
AU630598B2 (en) | Reduction of side effects of cancer therapy | |
US5605885A (en) | Method for stimulating the immune system | |
IL129211A (en) | Use of colostrinin in the manufacture of a medicament for the treatment of central nervous system disorders | |
JPH09508371A (ja) | 対宿主移植片疾患を予防するためのインターロイキン−12の使用 | |
US4250084A (en) | Purified thymic hormone (THF), its preparation and pharmaceutical compositions containing it | |
JPH09508116A (ja) | 末梢血単核細胞溶解活性を刺激するためのil−10の使用 | |
EA015510B1 (ru) | Способ увеличения количества мононуклеарных клеток у субъекта, страдающего раком, и используемая для этого фармацевтическая комбинация | |
AU714534B2 (en) | Immune-enhancing agent for therapeutic use in immunocompromised hosts | |
Sondel | Cellular immunotherapy of cancer: preclinical and clinical testing utilizing interleukin-2 | |
JPH03503647A (ja) | 黒色腫の治療のためのil‐2とdticとの組合せ療法 | |
US5317012A (en) | Human growth hormone induced improvement in depressed T4/T8 ratio | |
EP0447353B1 (en) | A pharmaceutical preparation for the maturation of prothymocytes | |
JPH06211692A (ja) | 免疫増強剤 | |
JPH0764744B2 (ja) | 標的細胞障害性因子とヒトインタ−フェロンとを有効成分として含有する悪性腫瘍治療剤 | |
JPH072690A (ja) | インターロイキン2を含有してなる免疫療法剤 | |
JPH06504767A (ja) | B−細胞悪性疾患の治療のための薬剤組成物 | |
JPH0219325A (ja) | 感染症を防除するためのヒト免疫グロブリンおよびインターロイキン―2の組み合わせ | |
Gunby | Research with immunoactive agents | |
Ershler et al. | Biological therapies in geriatric populations | |
MXPA97003626A (en) | Method for manufacturing a medicine to treat second secondary immunodeficiency | |
JPS6348225A (ja) | 制癌剤 | |
WO2006109285A1 (en) | Methods and compounds for the treatment of autoimmune diseases and chronic inflammatory conditions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20051220 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20051220 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060523 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060817 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20071030 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080222 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20080424 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20080515 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090213 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090219 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090312 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090317 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091008 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20091125 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121204 Year of fee payment: 3 |
|
LAPS | Cancellation because of no payment of annual fees |